Eikon Therapeutics reports company news centered on clinical-stage oncology development, financial results, public-company milestones, and capital-structure updates. Recurring developments include progress across EIK1001, EIK1003, and EIK1004, including lung cancer, prostate cancer, breast cancer, ovarian cancer, and advanced solid tumor programs.
The company’s news also covers corporate updates following its Nasdaq listing, shareholder voting matters, clinical or regulatory disclosures, and financial reporting for a late-stage biopharmaceutical issuer that operates through a single drug discovery and clinical development segment.
Eikon Therapeutics (EIKN) has appointed Ching-Pin (CP) Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer. He joins from Bristol Myers Squibb, where he was Vice President, Head of Cardiovascular Discovery Biology and Translational Pharmacology.
Dr. Chang previously led cardiovascular research at Gilead Sciences and served as Vice President of Disease Biology at MyoKardia, where he built a disease biology program focused on genetic causes of cardiomyopathies and the characterization of mavacamten for hypertrophic cardiomyopathy. He also held academic leadership roles at Stanford University and Indiana University School of Medicine, focusing on developmental genetics and heart failure. His training includes an M.D. from National Taiwan University, a Ph.D. in cancer biology from Stanford, and clinical and research fellowships at Massachusetts General Hospital, Stanford, and the Howard Hughes Medical Institute.
Eikon Therapeutics (Nasdaq:EIKN) announced that Chairman and CEO Roger M. Perlmutter and CFO Freddie Bowie will participate in two investor conferences in New York in September 2026: the 12th Annual Cantor Global Healthcare Conference on September 10 at 2:10 pm ET and the Morgan Stanley 24th Annual Global Healthcare Conference on September 15 at 4:05 pm ET, both in fireside chat format. Live and archived webcasts (for about 30 days) will be available via Eikon’s investor relations website.
Eikon Therapeutics (Nasdaq:EIKN) announced that Chairman and CEO Roger M. Perlmutter will participate in a Cantor Fitzgerald-hosted key opinion leader event on August 20, 2026 at 9:00 AM ET.
The session will feature MD Anderson oncologist Dr. Timothy A. Yap, an expert on PARP inhibitors, discussing their therapeutic use across several cancers. An archived webcast replay will be available on Eikon’s investor website for 30 days.
Eikon Therapeutics (Nasdaq: EIKN) reported second quarter 2026 results, highlighting major clinical and corporate progress. Seven abstracts featuring all four current clinical candidates (EIK1001, EIK1003, EIK1004, EIK1005) were accepted for presentation at the ESMO Congress 2026, building on data presented at ASCO 2026.
For EIK1001, an independent Data Monitoring Committee completed the first interim analysis of the TeLuRide-006 Phase 2/3 melanoma trial, selected a single dosing regimen, and recommended continuation. Eikon also dosed the first patient in TeLuRide-008, a Phase 2/3 NSCLC trial. Updated and initial data for EIK1003, EIK1004 and EIK1005 will be presented at ESMO.
Financially, Eikon ended June 30, 2026 with $531.2 million in cash, cash equivalents and marketable securities, which it expects will fund operations into the second half of 2027. Q2 2026 R&D expenses were $75.5 million (up 9% year over year), G&A expenses were $17.9 million (down 56%), and net loss attributable to common stockholders was $88.4 million versus $105.2 million a year earlier.
Eikon Therapeutics (Nasdaq: EIKN) announced that the ongoing adaptive Phase 2/3 TeLuRide-006 trial of EIK1001 in advanced melanoma will use a single dose of 0.60 mg/m2 for all patients randomized to EIK1001 treatment going forward. The choice follows a prespecified analysis of unblinded data by an independent Data Monitoring Committee (DMC).
According to Eikon, the DMC recommended that TeLuRide-006 continue as planned in all other respects. EIK1001 is described as activating myeloid and plasmacytoid dendritic cells to stimulate innate and adaptive immunity, and Eikon views the optimized dose selection as an important step in evaluating EIK1001 in combination with checkpoint inhibitors for advanced melanoma.
Eikon Therapeutics (Nasdaq: EIKN) appointed Johnny Bennett, Ph.D., Vice President and Head of Discovery Chemistry at Merck Research Laboratories, to its Scientific Advisory Board. The move extends Eikon’s long-standing relationship with Merck, which supplies KEYTRUDA for EIK1001 and EIK1005 clinical studies and participated in Eikon’s IPO.
Dr. Bennett is a medicinal chemist whose work at Organon led to the discovery of sugammadex (Bridion), earning major chemistry awards. He later held increasingly senior discovery chemistry and oncology roles at Merck. He joins a Board that includes Nobel laureates Eric Betzig and Thomas Cech and other prominent scientists.
Eikon Therapeutics (Nasdaq: EIKN) reported dosing the first patient in TeLuRide-008, a registrational Phase 2/3 trial of EIK1001 in combination with pembrolizumab and histology-appropriate chemotherapy. The study enrolls treatment-naïve patients with stage 4 Non-Small Cell Lung Cancer (NSCLC) receiving first-line therapy.
According to Eikon Therapeutics, EIK1001 is designed to stimulate both innate and adaptive immunity, enhance antigen presentation in secondary lymphoid tissues, and recruit a broader repertoire of T-cells. The company highlighted this first-patient dosing as a key milestone in advancing EIK1001 across multiple indications for patients with serious unmet medical needs.
Eikon Therapeutics (Nasdaq: EIKN) reported that seven abstracts covering its oncology pipeline have been accepted for presentation at the 2026 European Society of Medical Oncology (ESMO) Congress in Madrid, Spain.
According to Eikon, presentations will feature updated Phase 2 TeLuRide-005 data for EIK1001, a TLR7/8 dual agonist plus pembrolizumab and chemotherapy in stage IV non-small cell lung cancer, and details of the Phase 2/3 TeLuRide-008 study of EIK1001 in the same setting.
Additional Phase 1/2 data will highlight EIK1003, a PARP1-selective inhibitor, as monotherapy and in combination with paclitaxel in advanced solid tumors and with abiraterone in metastatic prostate cancer; EIK1004, a CNS-penetrant PARP1-selective inhibitor in advanced tumors with HRR mutations; and EIK1005, a Werner helicase inhibitor, including monotherapy and pembrolizumab combinations plus an analysis of its safety, tolerability and pharmacokinetics.
Eikon Therapeutics (Nasdaq:EIKN), a late-stage clinical biopharmaceutical company, will be added to the Russell 3000 Index following the annual reconstitution, effective after the US market closes on June 26, 2026.
The Russell 3000 measures about 3,000 US stocks, representing roughly 98% of the investable US equity market.
Eikon Therapeutics (Nasdaq:EIKN) appointed Ma. Fatima (Fama) D. Francisco as an independent director to its Board, effective June 15, 2026. She will also join the Board’s Compensation Committee.
Francisco brings over 35 years of leadership experience from Procter & Gamble and current board roles at HP and Nestle.